Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Dezember 2019 06:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex

Initiation of Phase 2 trial evaluating ganaxolone in tuberous sclerosis complex planned for 1H 2020 European Medicines Agency Orphan Drug Designation granted for ganaxolone for the treatment of CDKL5...
07. Dezember 2019 00:01 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting

100% of evaluable patients in target dose had no relapse during the four-week follow-up period Independent objective EEG seizure analysis confirms target dose Ganaxolone effective regardless of...
27. November 2019 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting

RADNOR, Pa., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
08. November 2019 16:00 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
06. November 2019 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

Positive Phase 2 IV ganaxolone data in RSE Strong enrollment continues in pivotal CDD study RADNOR, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a...
29. Oktober 2019 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer

RADNOR, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics...
17. Oktober 2019 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting

RADNOR, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics...
27. September 2019 16:05 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
26. September 2019 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October ...
23. August 2019 16:06 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RADNOR, Pa, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...

Vorherige Seite